With the goal to become a top 3 pharma company in China, Novartis has been busy tapping into the expertise of local ...

CDR-Life today announced the appointment of Pascal Touchon, DVM, MBA, to its Board of Directors. Dr. Touchon brings 40 years of international experience in the biopharmaceutical industry, with ...

At CTO West Coast an expert from Genentech outlined the company’s net zero goals, efforts, challenges and initiatives ...

Swiss pharma giant Novartis will spotlight key data across its oncology portfolio, including Kisqali (ribociclib), Scemblix ...

The international biotechnology company BeiGene is moving its legal headquarters from the Cayman Islands to Basel. In ...

This browser is no longer supported at MarketWatch. For the best MarketWatch.com experience, please update to a modern browser.

Steven H. Stein currently works at Repare Therapeutics, Inc., as Director from 2024, Incyte Corp., as Chief Medical Officer & Executive Vice President from 2016, the University of Pennsylvania, as ...

She joined Novartis more than 20 years ago and has led several of the company’s oncology businesses over the last six years, including region head of Novartis Oncology Europe.

NATALEE subanalysis evaluates Kisqali in pre-menopausal early breast cancer patients, amid rising diagnosis rates in younger patients Pluvicto analysis and Scemblix ASC4START primary endpoint results ...

A new study is the first phase 3 to show meaningful improvement in both progression-free and overall survival with first-line ...

It's the second deal involving FAP in the pace of 24 hours, after Lantheus Holdings acquired rights to NTI-1309, a PET oncology imaging agent that targets FAP, from Noria Therapeutics. Novartis ...

“BioNTech’s robust financial position empowers us to pursue our strategic goal of evolving into a leading biotech company with multiple oncology products by 2030.” Cost of sales was 83.8 ...